NEW YORK CITY, NY / ACCESS Newswire / November 18, 2026 / Levi & Korsinsky, LLP announces that a securities class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired EyePoint, Inc. (NASDAQ:EYPT) securities.

If you purchased NASDAQ:EYPT securities and suffered a loss, Learn about EyePoint, Inc. Class Action or call (212)363-7500 to speak to our team of experienced shareholder advocates.

THE LAWSUIT: A class action securities lawsuit was filed against EyePoint, Inc. that seeks to recover losses of EyePoint, Inc. shareholders who were adversely affected by alleged securities fraud between May 27, 2025 and August 14, 2026.

CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: EyePoint, Inc. shares fell roughly 73% to more than 80% after the Company reported that its Phase 3 LUCIA trial of DURAVYU in wet age-related macular degeneration failed its primary endpoint of non-inferiority to on-label aflibercept. In the trial, DURAVYU delivered approximately +2.5 letters mean BCVA change versus approximately +6.1 letters for the aflibercept control group. Concurrently, EyePoint announced the early conclusion of its wet AMD pivotal trials and a workforce reduction of approximately 53%, expected to generate approximately $30 million in annualized savings alongside approximately $9 million in one-time charges. In an October 15, 2025 Free Writing Prospectus, the Company previously represented that existing funds and offering proceeds would support operations into the fourth quarter of 2027, beyond Phase 3 wet AMD topline data for DURAVYU in 2026. Furthermore, during a March 4, 2026 earnings call, President and Chief Executive Officer Jay Duker stated, "we believe our wet AMD program is uniquely derisked and optimized to support success." In a September 10, 2026 SEC filing, EyePoint presented LUGANO topline results asserting non-inferiority by excluding nine patients who lost visual acuity from non-wet AMD etiologies. The investigation concerns whether EyePoint, Inc. adequately disclosed clinical trial risks and developmental timelines for DURAVYU ahead of the Phase 3 LUCIA primary endpoint failure.

WHAT'S NEXT? If you purchased EyePoint, Inc. securities during the relevant time frame, learn about your rights to seek a recovery. There is no cost or obligation to participate.

WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured billions of dollars for aggrieved shareholders. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees. For seven consecutive years, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212)363-7500
Fax: (212) 363-7171

Attorney Advertising. Prior results do not guarantee similar outcomes.

SOURCE: Levi & Korsinsky, LLP



View the original press release on ACCESS Newswire